The Enterprise Value as of September 2024 (TTM) for Gracell Biotechnologies Inc. (GRCL) is 5.45B

According to Gracell Biotechnologies Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 5.45B. This represents a change of 1.00% compared to the average of 495.40M of the last 4 quarters.

Gracell Biotechnologies Inc. (GRCL) Historical Enterprise Value (quarterly & annually)

How has GRCL Enterprise Value performed in the past?

The mean historical Enterprise Value of Gracell Biotechnologies Inc. over the last ten years is 3.64B. The current 5.45B Enterprise Value has changed 14.89% with respect to the historical average. Over the past ten years (40 quarters), GRCL's Enterprise Value was at its highest in in the September 2020 quarter at 11.07B. The Enterprise Value was at its lowest in in the March 2022 quarter at -447695625.43.

Gracell Biotechnologies Inc. (GRCL) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Gracell Biotechnologies Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Gracell Biotechnologies Inc. (GRCL) Average Enterprise Value

How has GRCL Enterprise Value performed in the past?

The current Enterprise Value of Gracell Biotechnologies Inc. (GRCL) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Gracell Biotechnologies Inc. (GRCL) Enterprise Value vs. Peers

How is GRCL’s Enterprise Value compared to its peers?

Gracell Biotechnologies Inc.’s Enterprise Value is greater than Theseus Pharmaceuticals, Inc. (138.26M), greater than Monte Rosa Therapeutics, Inc. (284.72M), greater than Design Therapeutics, Inc. (221.42M), greater than Erasca, Inc. (689.13M), greater than NextCure, Inc. (25.04M), greater than CytomX Therapeutics, Inc. (62.24M), greater than Neoleukin Therapeutics, Inc. (-6333315.00), greater than Spero Therapeutics, Inc. (12.49M), greater than Assembly Biosciences, Inc. (90.35M), greater than Terns Pharmaceuticals, Inc. (458.36M), greater than Amylyx Pharmaceuticals, Inc. (89.50M), greater than Acumen Pharmaceuticals, Inc. (93.64M), greater than Inozyme Pharma, Inc. (343.89M), greater than X4 Pharmaceuticals, Inc. (40.79M), greater than Bolt Biotherapeutics, Inc. (37.47M), greater than Coherus BioSciences, Inc. (281.96M), greater than Icosavax, Inc. (713.87M), greater than Day One Biopharmaceuticals, Inc. (1.01B), greater than Decibel Therapeutics, Inc. (96.42M), less than Blueprint Medicines Corporation (6.16B),

Build a custom stock screener for Gracell Biotechnologies Inc. (GRCL) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Gracell Biotechnologies Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Gracell Biotechnologies Inc. (GRCL) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Gracell Biotechnologies Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.